WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/042089    International Application No.:    PCT/EP1999/000886
Publication Date: 26.08.1999 International Filing Date: 11.02.1999
Chapter 2 Demand Filed:    27.08.1999    
A61K 31/437 (2006.01)
Applicants: ROCHE DIAGNOSTICS GMBH [DE/DE]; Sandhofer Strasse 116, D-68305 Mannheim (DE) (For All Designated States Except US).
FRIEBE, Walter-Gunar [DE/DE]; (DE) (For US Only).
SCHAUMANN, Wolfgang [DE/DE]; (DE) (For US Only).
WILHELMS, Otto-Henning [DE/DE]; (DE) (For US Only)
Inventors: FRIEBE, Walter-Gunar; (DE).
SCHAUMANN, Wolfgang; (DE).
WILHELMS, Otto-Henning; (DE)
Agent: WITTE, Hubert; Grenzacherstrasse 124, CH-4070 Basle (CH)
Priority Data:
98102675.0 17.02.1998 EP
Abstract: front page image
(EN)Use of compounds of the formula (I), in which X and X, identically or differently, are hydrogen, a C - to C -alkyl radical or a halogen atom or, if they are in adjacent positions, form a fused phenyl ring together with the carbon atoms carrying them, and R is an optionally substituted carbocyclic or heterocyclic saturated or unsaturated radical, and their physiologically tolerable salts, for the production of medicaments for diseases which are modulated via inhibition of phosphodiesterase(s) by cyclic nucleotides, in particular cyclic adenosine monophosphate. The diseases are more particularly proliferative disorders, including tumors, lymphomas, leukaemias, atherosclerosis and glomerulopathies, memory and/or learning ability disorders (inter alia Alzheimer's), impotence, erectile insufficiency and obesity, ischaemic or thrombolytic disorders, such as coronary infarct or cerebral infarct and additionally serum disorders.
(FR)Cette invention, qui a trait à l'emploi de composés correspondant à la formule (I) dans laquelle X?1¿ et X?2¿, de manière identique ou différente, représentent un hydrogène, un radical alkyle portant de 1 à 6 atomes de carbone ou un atome d'halogène ou bien, s'ils se trouvent sur des positions adjacentes, forment un phényle à anneaux condensés avec les atomes de carbone les portant et dans laquelle R représente un radical carbocyclique ou hétérocyclique, saturé ou insaturé, éventuellement substitué, concerne également les sels physiologiquement admissibles de ces composés et ce, aux fins de la préparation de médicaments destinés à traiter des affections modulées, via l'inhibition d'une phosphodiestérase ou de phosphodiestérases, par des nucléotides cycliques, notamment l'adénosine-monophosphate cyclique.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)